Insights from FDA Commissioner Marty Makary on the All-In Podcast/Interview

FDA Commissioner Marty Makary was on the All-In Podcast/Interview this week. Here are some of the new tidbits relating to the FDA from the interview:

• Mention there will be a whole new line of accelerated review pathways (details not mentioned).
• 2026 goal for more drugs to be available without prescription. This will be for drugs that do not have abuse potential, are 'safe' and do not have lab monitoring requirements.
• Every FDA Approve or Reject decision was consistent with the recommendation from the review team.
• First Commissioner's National Priority Voucher review was completed in 55 days.
• FDA hiring 1050 new scientists.

Source: Link to Podcast